1

                                                                    Exhibit 99.2

                          RESMED ANNOUNCES PRICING OF
                 $150 MILLION OF CONVERTIBLE SUBORDINATED NOTES

San Diego, CA, June 15, 2001- ResMed Inc. (NYSE: RMD) announced today that it
has entered into a purchase agreement providing for the sale to certain initial
purchasers of $150 million of convertible subordinated notes due 2006 ($180
million if the over-allotment option is exercised in full). The initial
purchasers' over-allotment option was increased from $22.5 million to $30
million. The offering of the notes, which was made within the United States only
to qualified institutional buyers and outside the United States to non-U.S.
qualified investors, is expected to close on June 20, 2001.

The notes are convertible into ResMed common stock at a price of $60.60 per
share, subject to adjustment in certain circumstances. This represents a 20%
premium over the last reported trade on June 14, 2001 of $50.50. The notes bear
interest at 4% per annum, have a five-year term and can be redeemed by ResMed at
any time subject to certain limitations.

ResMed intends to use a portion of the net proceeds of the note offering to
repay its outstanding indebtedness incurred in connection with its February 2001
acquisition of MAP Medizin-Technologie GmbH and amounts outstanding under its
existing credit facility. The remaining proceeds will be used for general
corporate purposes, including working capital, the development and introduction
of new products and the introduction of its products into new markets.

The notes and underlying common stock have not been registered under the
Securities Act of 1933 or applicable state securities laws, and may not be
offered or sold in the United States absent registration or an applicable
exemption from the registration requirements of the Securities Act and
applicable state laws. This announcement shall not constitute an offer to sell
or a solicitation of an offer to buy the notes.

ResMed is a leading developer, manufacturer, and marketer of medical equipment
for the diagnosis and treatment of sleep-disordered breathing, selling its
products in 60 countries. ResMed made the Forbes' list of 200 Best Small
Companies in America for four consecutive years; in 2000, ResMed was ranked #34
up from #172 in 1997. ResMed was listed as one of Business Week's Hundred Hot
Growth Companies for three consecutive years; in 2001 ResMed was ranked #31 up
from 67 in 1999. ResMed was named by Fortune magazine as one of America's One
Hundred Fastest Growing Companies in both 1999 and 2000.

Statements contained in this release, which are not historical facts, are
"forward-looking" statements as contemplated by the Private Securities
Litigation Reform Act of 1995. Such forward-looking statements are subject to
the risks and uncertainties, which could cause actual results to differ
materially from those projected or implied in the forward-looking statements.
Such risks and uncertainties include, among others, general economic, financial
and business conditions, the potential inability to complete the note offering
and other factors discussed in the Company's Annual Report on Form 10-K for the
most recent fiscal year.

Further information can be obtained by contacting Walter Flicker at ResMed Inc.,
(858) 746-2211 or by visiting the Company's multilingual web site at
www.resmed.com.